DRIVEN BY SCIENCE
FOCUSED ON LIFE
Nuvation Bio is focused on treating patients with the most difficult-to-treat cancers, for which conventional therapies have failed.
Nuvation Bio January 2021 Presentation
LATEST PRESS RELEASES
“My founding vision for Nuvation Bio is to develop new generations of oncology medicines that will meaningfully improve patient lives by addressing drug resistance or limited efficacy of current therapies, while reducing side effects and preserving quality of life for cancer patients. We are focused on developing novel oncology therapeutic agents for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies have failed. To that end, we have created a deep pipeline of differentiated and novel investigational oncology therapeutic candidates that target some of the most critical pathways that cancer cells use to grow. We have demonstrated, in preclinical studies, the potential of those candidates to significantly improve outcomes over current standards of care.”
– David Hung, M.D., Founder and Chief Executive Officer